
doi: 10.1021/pr0703674
pmid: 17803295
TOPORS is the first example of a protein with both ubiquitin and SUMO-1 E3 ligase activity and has been implicated as a tumor suppressor in several different malignancies. To gain insight into the cellular role of TOPORS, a proteomic screen was performed to identify candidate sumoylation substrates. The results indicate that many of the putative substrates are involved in chromatin modification or transcriptional regulation. Transfection studies confirmed mammalian Sin3A as a sumoylation substrate for TOPORS. These findings suggest that TOPORS may function as a tumor suppressor by regulating mSin3A and other proteins involved in chromatin modification.
Recombinant Fusion Proteins, Ubiquitin-Protein Ligases, Molecular Sequence Data, SUMO-1 Protein, Nuclear Proteins, Transfection, Chromatin, Neoplasm Proteins, Repressor Proteins, Sin3 Histone Deacetylase and Corepressor Complex, Cell Line, Tumor, Humans, Amino Acid Sequence
Recombinant Fusion Proteins, Ubiquitin-Protein Ligases, Molecular Sequence Data, SUMO-1 Protein, Nuclear Proteins, Transfection, Chromatin, Neoplasm Proteins, Repressor Proteins, Sin3 Histone Deacetylase and Corepressor Complex, Cell Line, Tumor, Humans, Amino Acid Sequence
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 58 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
